25
Participants
Start Date
March 21, 2023
Primary Completion Date
March 1, 2026
Study Completion Date
January 1, 2027
Embozene particles
Embozene particles are FDA approved for the embolization of hypervascular tumors and arteriovenous malformations. Several studies have shown excellent safety and efficacy with regards to tumor control and objective response in liver cancer. It has been used extensively for the treatment of symptomatic uterine fibroids, where Embozene embolization of the uterine arteries results in necrosis of uterine fibroids and cessation of abnormal vaginal bleeding. Other proven uses include embolization of arteriovenous malformations and fistulas.
RECRUITING
University of California, Los Angeles, Los Angeles
Siddharth Padia, MD
OTHER